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Abstract Methylglyoxal (MGO) can modify tissue proteins
through the Maillard reaction, resulting in advanced glycation
end products (AGEs), which can alter protein structure and
functions. Several MGO-derived AGEs have been described,
including argpyrimidine, a £uorescent product of the MGO re-
action with arginine residues. We detected signi¢cant amount of
argpyrimidine in rat kidney mesangial cells cultured in media
containing high concentrations of glucose. Heat shock protein
27 (Hsp27) was identi¢ed by liquid chromatography tandem
mass spectrometry as a major anti-argpyrimidine immunoreac-
tive protein. We con¢rmed this ¢nding by reciprocal co-immu-
noprecipitation and by Western analysis. Diabetic rats con-
tained more argpyrimidine-modi¢ed glomerular Hsp27 than
non-diabetic animals. Additional studies showed that MGO-in-
duced modi¢cation of Hsp27 decreased its binding to cyto-
chrome c. Our results suggest that Hsp27 is a major target
for MGO modi¢cation in mesangial cells.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Key words: Mesangial cell ; Methylglyoxal ; Diabetes ;
Heat shock protein 27; Cytochrome c
1. Introduction
The non-enzymatic glycation of proteins in a high glucose
environment occurs via the Maillard reaction [1]. Aldehydes
and ketones react with amino groups on proteins to produce
advanced glycation end products (AGEs), which may include
amino acid cross-links, £uorophores, and chromophores [1,2].
AGEs bind to speci¢c receptors on cells, where they can dam-
age the a¡ected tissues by causing intracellular oxidative stress
as well as the synthesis of growth factors and cytokines [3,4].
Evidences suggest that AGEs contribute to the development
of glomerular lesions of diabetes [5]. In addition, AGE-modi-
¢ed proteins stimulate a variety of cellular responses via spe-
ci¢c cell surface receptors on several cell types including glo-
merular mesangial cells [6^8].
Mesangial cells grown on various AGE-modi¢ed matrix
proteins exhibit altered functions, such as enhanced produc-
tion of ¢bronectin and decreased cell proliferation. Aldehyde-
modi¢ed matrix macromolecules, such as laminin and ¢bro-
nectin, can inhibit mesangial cell adhesion, and mesangial cells
grown on glyceraldehyde-modi¢ed ¢bronectin have dimin-
ished mitogenic activity [9]. Results from these studies clearly
implicate AGE-modi¢ed proteins in mesangial cell damage in
vitro and suggest that similar changes occur in the setting of
diabetic renal disease.
Reactive dicarbonyl compounds such as glyoxal and meth-
ylglyoxal (MGO) are major intermediates in Maillard reac-
tions [10]. MGO originates from various biochemical path-
ways, including the dephosphorylation of glycolytic
intermediates, metabolites of the polyol pathway, and from
aminoacetone metabolism [11]. Several tissues and plasma of
diabetic individuals exhibit increased amounts of MGO [12].
MGO can modify amino acids, nucleic acids and proteins,
and arginine appears to be a primary target in protein mod-
i¢cation [12,13]. Several arginine modi¢cations have been de-
scribed [14] and one major modi¢cation is argpyrimidine
which is a blue £uorescent AGE. It has been detected in the
human lens and in cultured bovine retinal endothelial cells
[15^18].
Because plasma levels of MGO are elevated in diabetes and
MGO increases the susceptibility of mesangial cells to apopto-
sis [19], we believe that MGO-mediated Maillard reactions are
involved in diabetic renal disease. In fact some studies have
suggested that mesangial cells undergo apoptosis in diabetic
kidneys [19,20]. A recent study has suggested a direct role for
AGEs in such apoptotic cell death [21]. We investigated the
formation of argpyrimidine in rat glomerular mesangial cells
that were cultured in high concentrations of glucose and in
glomeruli isolated from normal and diabetic animals. We also
report argpyrimidine formation in heat shock protein 27
(Hsp27), a stress protein, and the consequences of MGO-
mediated Maillard reactions on its binding to cytochrome c
(cyt c).
2. Materials and methods
2.1. Materials
Monoclonal antibody to argpyrimidine was from Dr. Koji Uchida,
Nagoya University, Japan; goat antibody to Hsp27 was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), and antibody to cyt c
was from BD Transduction Laboratories (San Diego, CA, USA).
CNBr-activated Sepharose 4B was from Amersham-Pharmacia Bio-
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tech (Piscataway, NJ, USA). All secondary antibodies and protein
A/G agarose gel were from Santa Cruz Biotechnology.
2.2. In vivo tissues
Kidneys were isolated from male Sprague^Dawley rats. Diabetes
was induced by a single intraperitoneal injection of streptozotocin
(60 mg/kg body weight). Diabetic animals received 2 U of NPH hu-
mulin once every 4 days to maintain the body weight. Body weight,
plasma glucose concentrations and HbA1c in these animals were mea-
sured and shown in Table 1. We compared tissue from diabetic ani-
mals (5 months duration) with non-diabetic controls of the same age
and weight. The Case Western Reserve University IACAU Committee
approved all animal use protocols.
2.3. Mesangial cell culture
Glomeruli were obtained from rat kidneys by a standard sieving
technique [22]. Mesangial cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with 5.6 mM glucose, 110
mg/ml sodium pyruvate, 100 U/ml penicillin G, 100 Wg/ml streptomy-
cin, and 15% fetal bovine serum (FBS). Mesangial cells were identi¢ed
using an antibody against vascular smooth muscle myosin [23]. Me-
sangial cells (at 6^12 passages) were cultured for a week in DMEM
with either 5.6 or 30 mM D-glucose; cultures in 30 mM L-glucose
served as osmotic controls. Cultures were replenished with fresh
growth media (with or without external glucose) every 48 h. After
1 week of incubation, the medium was replaced with serum-poor
medium (0.5% FBS) that contained all other additives, and the cells
were incubated for another 48 h. After serum starvation the cells were
lysed and protein concentration of lysates was measured using the
Micro BCA assay (Pierce, Rockford, IL, USA) [23].
2.4. Argpyrimidine in mesangial cells
Intracellular formation of argpyrimidine was assessed by immuno-
histochemistry [18]. Mesangial cells were cultured as described above
in eight-well chamber slides (Nalge Nunc International, Naperville,
IL, USA). The cells were ¢xed with 4% paraformaldehyde and per-
meabilized with 80% methanol. The wells were blocked with 5% non-
fat dry milk in phosphate-bu¡ered saline (PBS) (pH 7.4), incubated
with anti-argpyrimidine antibody followed by rhodamine-conjugated
anti-mouse IgG (Chemicon International, Temecula, CA, USA). The
slides were mounted in a medium (Biomeda corp., Foster City, CA,
USA) and observed under an Olympus £uorescence microscope
(Olympus Optical Company, Japan).
2.5. Protein identi¢cation by liquid chromatography tandem mass
spectrometry (LC MS/MS)
Coomassie blue-stained sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE) gel bands were excised, digested in situ
with trypsin and tryptic peptides analyzed by LC MS/MS using a
quadrupole time of £ight (QTOF2) mass spectrometer equipped
with a CapLC system (Micromass) as described [24]. Peptide digests
were trapped on a C18 precolumn (e.g. 0.3U1 mm, LC Packing) with
0.1% formic acid in 2% acetonitrile as loading solvent and then eluted
onto a capillary C18 column (e.g. PicoFrit 0.050U50 mm, 15 W tip ID,
New Objective, Inc.). Chromatography was performed at 250 nl/min
with aqueous acetonitrile/formic acid solvents and 100% of the eluant
directed into the mass spectrometer. MS/MS spectra were collected
over the range m/z 50^2000, ProteinLynx Global Server, MassLynx
version 3.5 and the Swiss-Protein and NCBI protein sequence data-
bases (February 2003).
2.6. Immunoprecipitation
Cell lysates were incubated overnight at 4‡C with monoclonal arg-
pyrimidine antibody or goat polyclonal antibody to Hsp27. Protein
A/G agarose was added, and the mixture was further incubated at
4‡C for 2 h. The agarose resin was then washed four times with im-
munoprecipitation bu¡er containing 10 mM HEPES (pH 7.4) with
150 mM NaCl, 5 mM ethylenediamine tetraacetic acid (EDTA) and
protease inhibitors, and the ¢nal pellet was suspended in SDS sample
bu¡er.
2.7. SDS^PAGE and Western blotting
Proteins were separated by electrophoresis on 18% SDS^polyacryl-
amide denaturing gels and transferred to nitrocellulose membrane.
The blots were probed with antibodies to either argpyrimidine or
Hsp27. The immunoblots were developed with the appropriate sec-
ondary antibody linked to horseradish peroxidase (Sigma and Santa
Cruz) and enhanced chemiluminescence (ECL) kit (Perkin-Elmer Life
Sciences, Boston, MA, USA).
2.8. Immunostaining of kidney sections
Immunohistochemistry was done according to standard procedures.
Methacarn-¢xed para⁄n-embedded tissue sections were incubated
with the argpyrimidine antibody and the reaction was developed
with secondary biotinylated antibody (Vector Laboratories, Burlin-
game, CA, USA). The slides were stained with Vector ABC reagent
(Vector Laboratories), then counterstained with hematoxylin and
mounted.
2.9. MGO modi¢cation of Hsp27 and binding to cyt c
To study the e¡ect of MGO modi¢cation on Hsp27, we mixed 25 Wg
of recombinant human Hsp27 (StressGen Biotechnologies Corp., Vic-
toria, BC, Canada) with 50 and 200 WM of MGO and incubated the
mixture at 37‡C for 16 h in 50 mM HEPES bu¡er (pH 7.6). Incuba-
tions of Hsp27 with bu¡er alone served as controls. After incubation,
the mixtures were dialyzed extensively against 50 mM HEPES^NaOH
(pH 7.6) to remove excess MGO. We assessed binding of control and
MGO-modi¢ed Hsp27 (10 Wg each) to cyt c by incubating samples
with 20 Wg of cyt c (Sigma) in the presence of 1 mM deoxyadenosine
triphosphate (dATP) [25]. Cyt c was immunoprecipitated using a
mouse anti-cyt c monoclonal antibody [26]. The immunocomplexes
were separated by incubation with protein A/G. The pellet was
washed ¢ve times with 50 mM HEPES^NaOH (pH 7.6) that had
protease inhibitors. The immunoblots were developed with antibody
to Hsp27 or anti-cyt c and ECL kit as described above. In addition to
the above method, we studied the binding of cyt c to Hsp27 after
directly coupling Hsp27 (25 Wg/ml) to CNBr-activated Sepharose 4B
according to the manufacturer’s protocols (Amersham Pharmacia
Biotech). The gel was washed extensively with PBS to remove the
unbound Hsp27. The Hsp27 bound to Sepharose beads was either
used as control (unmodi¢ed) or was modi¢ed by incubating with
5 mM of MGO for 16 h at 37‡C. The binding of cyt c to Hsp27
was tested as described above followed by Western blotting.
3. Results
3.1. Argpyrimidine in mesangial cell proteins
Mesangial cells exposed to high concentrations of either
glucose (30 mM D-glucose) or MGO (50 WM) accumulate
greater quantities of argpyrimidine than cells cultured in un-
altered media based on immuno£uorescence detection of arg-
pyrimidine with monoclonal antibody (Fig. 1). We detected
immuno£uorescence throughout the cells but noted highest
immunoreactivity in the perinuclear region.
To evaluate whether argpyrimidine formation was associ-
ated with speci¢c proteins, we examined the cytosolic proteins
by Western blotting. These experiments compared cytosolic
proteins from cells grown in 5.6 and 30 mM D-glucose and
as shown in Fig. 2, a single argpyrimidine immunoreactive
protein band of about 27 kDa was detected under the exper-
Table 1
Body weight, plasma glucose and HbA1c in control and diabetic rats
Group Body weight (g) Plasma glucose (mg/dl) HbA1c
Control 628S60 76S 9 5.2S 1.0
Diabetic 299S59 413S 39 14.3S 1.4
Data are meanSS.D. Rats were diabetic for 5 months (n=10 in each group).
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imental conditions. The intensity of the immunoreactive pro-
tein was higher with 30 mM D-glucose-incubated cells when
compared to either 5.6 mM D-glucose or 30 mM L-glucose-
incubated cells (osmotic control media). It is noteworthy that
if the medium was not changed during the 7-day incubation
there was no obvious increase in argpyrimidine content in the
27-kDa protein in cells that were cultured in 30 mM D-glucose
when compared to those in 5.6 mM D-glucose. A protein band
of comparable intensity to that seen in cells incubated with
5.6 mM glucose was detected in preparations from cells incu-
bated with 30 mM L-glucose (data not shown). This could
indicate that MGO modi¢es a 27-kDa protein in cells cultured
under basal incubation conditions, and that the protein was
further modi¢ed in cells exposed to high concentrations of
D-glucose.
3.2. Argpyrimidine in rat kidney glomeruli and 27-kDa protein
The next step was to determine if diabetes enhanced for-
mation of argpyrimidine in the kidney. Immunostaining for
argpyrimidine in sections from normal and diabetic rat kid-
neys indicated a greater intensity of staining in glomeruli from
diabetic animals than those from non-diabetic controls (Fig.
3A and B). To determine if the 27-kDa protein accounted for
the observed immunoreactivity, we isolated glomeruli from
normal and diabetic rat kidneys. We then extracted the pro-
teins with a 60 mM Tris bu¡er (pH 7.0) containing 0.25 M
sucrose, 2 mM EDTA and 1 mM L-mercaptoethanol and 10%
SDS. Fig. 4 shows a Western blot with antibody to argpy-
rimidine, indicating that diabetic rats have argpyrimidine as-
sociated with the 27-kDa protein while the non-diabetic con-
trols do not.
Fig. 1. Detection of argpyrimidine by immuno£uorescence. Mesangial cells were cultured in medium with 5.6 (A) or 30 mM D-glucose (B) and
stained for argpyrimidine. C shows cells that were incubated with 50 WM MGO for 72 h in standard (5.6 mM glucose) medium. Cells in
30 mM L-glucose were osmotic controls (D). The antibody was blocked with 1 nmol of argpyrimidine before addition to 30 mM D-glucose-
treated cells (E). Magni¢cation= 400U.
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3.3. Identi¢cation of 27 kDa as Hsp27
Immunoprecipitation and LC MS/MS con¢rmed that
Hsp27 was the argpyrimidine-containing protein. Cell lysate
proteins were incubated ¢rst with antibodies to Hsp27 or
argpyrimidine, then immunoprecipitated by protein A/G aga-
rose, and separated by SDS electrophoresis. Western blot
analysis of the immunoprecipitation products with antibodies
to either argpyrimidine or Hsp27 (Fig. 5A) showed that
Hsp27 co-immunoprecipitated with both antibodies. The arg-
pyrimidine immunoreactive 27-kDa band in the immunopre-
cipitated proteins was excised from a separate Coomassie
blue-stained SDS^PAGE gel, digested in situ with trypsin
and the peptides were analyzed by LC MS/MS. The mass
spectrometric analysis revealed 10 tryptic peptides that
matched with internal sequences of Hsp27. Together these
results strongly support the identity of the argpyrimidine-con-
taining 27-kDa protein as Hsp27.
To evaluate whether rat glomerular Hsp27 increases in dia-
betes, we performed Western blot analysis of glomerular ly-
sates with antibodies to Hsp27 (Fig. 5B) and found that glo-
meruli from diabetic animals have greater immunoreactivity
than those from non-diabetic controls. This may be respon-
sible, in part, for the higher argpyrimidine immunoreactivity
in diabetic glomeruli (Figs. 3 and 4).
3.4. MGO modi¢cation of Hsp27 reduces its binding to cyt c
Since binding of cyt c by Hsp27 inhibits the mitochondrial
pathway of apoptosis [26], we speculated that argpyrimidine
modi¢cation might in£uence Hsp27 binding to cyt c. To ex-
amine this possibility, Hsp27 was incubated with 50 WM
MGO for 20 h at 37‡C, then dialyzed against 50 mM
HEPES^NaOH (pH 7.6) and incubated with cyt c in the pres-
ence of dATP. The Hsp27^cyt c complex was immunopreci-
pitated with antibody to cyt c and protein A/G agarose, sep-
arated by SDS^PAGE and Western blotted with anti-Hsp27
antibody. Modi¢ed Hsp27 bound slightly less cyt c than the
unmodi¢ed protein when exposed to 50 WM MGO (Fig. 6A)
Fig. 2. Argpyrimidine-bearing proteins in mesangial cells. Proteins
(100 Wg each) from cultured mesangial cells were separated by 15%
SDS^PAGE, blotted onto nitrocellulose membranes and probed
with antibody to argpyrimidine. Lane 1, mesangial cells cultured in
5.6 mM glucose; lane 2, cells cultured in 30 mM D-glucose; lane 3,
MGO-modi¢ed bovine serum albumin (BSA) (positive control);
K-tubulin (loading control).
Fig. 3. Argpyrimidine in normal and diabetic rat kidneys. Kidneys
from rats that were diabetic for 5 months were compared with non-
diabetic controls. Tissues were processed for immunohistochemistry.
A shows a representative glomerulus from normal rat kidney section
immunostained with antibody to argpyrimidine. B shows a represen-
tative glomerulus from diabetic rat kidney section immunostained
with antibody to argpyrimidine.
Fig. 4. Western blot of glomerular lysates for argpyrimidine. Equal
amounts (50 Wg) of glomerular protein from normal or diabetic ani-
mals were probed with antibody to argpyrimidine or K-tubulin
(loading control).
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and signi¢cantly less cyt c when incubated with 200 WM MGO
(Fig. 6B). To further con¢rm these observations, we conju-
gated Hsp27 onto CNBr-activated Sepharose 4B. The Hsp27
bound to Sepharose was then modi¢ed by incubation with
MGO and then reacted with cyt c. As shown in Fig. 6C, there
was signi¢cantly less binding of cyt c to MGO-modi¢ed
Hsp27 when compared to unmodi¢ed Hsp27. These results
suggest that Hsp27 modi¢cation by MGO reduces its ability
to bind to cyt c.
4. Discussion
We originally planned to identify the major MGO-AGE-
bearing proteins in mesangial cells in order to assess how
speci¢c changes in these proteins relate to abnormalities of
renal function in diabetes. Unexpectedly, we found high levels
of argpyrimidine in Hsp27 from cell lysates of cultured rat
mesangial cells. It is possible that the arginine residues in
Hsp27 are more accessible for reaction with MGO compared
to other proteins, and could explain its high immunoreactivity
with anti-argpyrimidine antibody. Recently, Sakamoto et al.
[27] have reported argpyrimidine formation in Hsp27 in can-
cer cells that were incubated with high concentrations of glu-
cose. These results support our view that Hsp27 is the primary
target for MGO modi¢cation in cells.
Our observation that argpyrimidine content in Hsp27 in-
creased under high glucose conditions in rat mesangial cells
suggests that this protein is speci¢cally modi¢ed in the dia-
betic kidney glomeruli. In fact, our results from immunostain-
ing of rat kidneys support this view. The presence of argpy-
rimidine in Hsp27 under normoglycemic conditions suggests
the formation of low levels of MGO in these cells. One pos-
sible pathway of MGO formation is through oxidative stress.
If cells in culture are under a mild oxidative stress, it could
lead to formation of MGO. In fact, other investigators
showed that oxidative stress promotes MGO production in
cultured cells [28]. There are reports that glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), the enzyme that con-
verts glyceraldehyde-3-phosphate (G3P) to 1,3-diphosphogly-
cerate, is inactivated due to oxidative stress and hyperglyce-
mia [29^31]. A loss in GAPDH activity would permit
accumulation of G3P, which can be spontaneously converted
to MGO by L-elimination of the phosphate group. In addi-
tion, oxidative stress may enhance degradation of the Ama-
dori product, an initial condensation product of glucose and
lysine residues on proteins, and/or promote autoxidation of
sugars [32]. A recent study suggested that activation of thi-
amine-dependent transketolase, that channels G3P to HMP
shunt pathway can lower MGO levels in endothelial cells
[33]. Any or all of these processes could contribute to MGO
formation. Unfortunately, we were unable to measure MGO
directly in mesangial cells, but work from other laboratories
supports our idea that MGO formation plays an important
role in renal cell damage. For example, Brownlee’s group
found that normalization of mitochondrial superoxide pro-
duction attenuates major pathways of diabetic complications,
including formation of intracellular AGEs [31].
The ready detection of argpyrimidine in kidneys from dia-
betic rats, and the association of argpyrimidine with glomer-
ular Hsp27 suggest that in diabetes, MGO production is en-
hanced within mesangial cells through an increase in oxidative
stress and/or enhancement in glucose £ux through metabolic
pathways. It is not known whether external MGO can enter
mesangial cells. Intracellular estimation of MGO would have
provided a clearer picture, but we were unable to perform
such measurements because of lack of adequate sensitivity
of the MGO assays. Moreover, we investigated only one mod-
i¢cation of MGO, it is likely that other modi¢cations could
occur along with argpyrimidine under hyperglycemic condi-
tions. Whether their synthesis would be enhanced by external
Fig. 5. Hsp27 and argpyrimidine in cell lysates and glomerular ex-
tracts. Lysates of mesangial cells cultured in 5.6 mM D-glucose (A)
were immunoprecipitated with argpyrimidine antibody and protein
A/G agarose, then probed with antibodies to either argpyrimidine
or Hsp27. B shows Western blot of kidney glomerular lysates from
normal or diabetic animals. Proteins (50 Wg each) were separated by
SDS^PAGE and probed with antibody to Hsp27.
Fig. 6. MGO-induced modi¢cation on Hsp27 a¡ects binding to cyt
c. Hsp27 was reacted with 50 or 200 WM MGO, incubated with cyt
c and dATP for 1 h at 30‡C and the cyt c^Hsp27 complex was im-
munoprecipitated using antibodies to cyt c. Western blots were
probed with anti-Hsp27 antibody. Control lysates in both panels are
lysates from mesangial cells cultured in 5.6 mM D-glucose medium.
A shows Hsp27 incubated with 50 WM of MGO and B is for Hsp27
incubated with 200 WM MGO. C: Hsp27 was coupled to CNBr-ac-
tivated Sepharose 4B and then incubated with or without 5 mM
MGO for 16 h. The gel was washed extensively after the incubation
and reacted with cyt c for 2 h. After extensive washing of the gel,
binding of cyt c was assessed by Western blotting using an anti-cyt
c antibody.
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MGO is unknown. In the event that MGO is impermeable in
mesangial cells, a likely mechanism is the enhanced £ux of
glucose under hyperglycemic conditions, which could lead to
higher concentrations of glycolytic intermediates that can
spontaneously produce MGO. Other mechanisms, such as
those described above may also play a role. The higher im-
munoreactivity for argpyrimidine in diabetic glomeruli could
also be due to higher content of Hsp27 (see below).
The stress protein Hsp27 is upregulated under certain con-
ditions, e.g. oxidative stress, to protect cells from uncontrolled
apoptosis. In fact, our results show that in diabetes, Hsp27
content is increased in the glomerulus. Hsp27 appears to in-
terfere speci¢cally with the mitochondrial pathway of caspase-
dependent cell death [26]. Hsp27 inhibits cyt c-mediated acti-
vation of caspases by binding to cyt c and thereby preventing
cyt c-mediated interaction of Apaf-1 with procaspase-9
[26,34]. Our in vitro experiments showed that cyt c binding
of Hsp27 is reduced after chemical modi¢cation of Hsp27 by
MGO, suggesting that argpyrimidine, and possibly other
MGO-AGEs, compromises the ability of Hsp27 to prevent
apoptotic cell death. A recent report suggested that MGO
induces apoptosis of rat mesangial cells [19]. Argpyrimidine
formation may compromise other functions of Hsp27 as well.
For example, Hsp27 serves as a chaperone to stabilize cyto-
skeletal proteins [35]. Cytoskeletal breakdown is a key event
in the initiation of apoptosis [36].
In summary, results from our experiments show that me-
sangial cell Hsp27 is chemically modi¢ed by MGO; this phe-
nomenon occurs both in cell cultures and in an animal model
of diabetes. We ¢nd that MGO-mediated modi¢cation of
Hsp27 reduces its binding to cyt c. This structural change of
a major stress protein is likely to play a role in altered me-
sangial cell functions in diabetes.
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